The current work examined the potential of utilizing ARV-825 and ABBV-744 to enhance the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in both p53 wild-type (WT) breast tumor cells As well as in cells lacking purposeful p53 both by itself or in combination with tamoxifen, when the https://abbv-744-and-other-brd4-i79124.targetblogs.com/32476873/brd4-targeted-therapy-abbv-744-clinical-data-no-further-a-mystery